Additional file 1: of Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification

Figure S1. Methods, antibodies and validation that IIC-density does not correlate with patient clinicopathological characteristics. Figure S2. CD45 distribution on TMA cores and K-M plots of immune cells and Ki-67. Figure S3. Five-color panels demonstrate which ICP subsets preferentially label TIL. Figure S4. Effect of applied treatments on OS of TMA patient cohort. Figure S5. Validation of effect of ICP signature on additional NSCLC cohorts and cancers. Figure S6. MP-IF ICP combination panels stratifying NSCLC patients. Figure S7. Kaplan-Meier survival analysis of principle components positively associated with OS. Figure S8. ICP coexpression ranking demonstrates ICP subset. Figure S9. Timing of effects of ICP expression on Kaplan-Meier survival curves. Figure S10. Compressed view of refined ICP-interactors presented in Fig. 7. Figure S11. Word-cloud analysis of top ICP interactors and associated pathways. Table S1. Clinicopathologic characteristics of TMA cohort. Table S2. Correlations between clinicopathological characteristics of TMA cohort. Table S3. Antibodies used in the study. Table S4. Correlations of TMA ICP MFI with immunogenicity and clinical characteristics. Table S5. Correlations of TMA ICP counts with immunogenicity and clinical characteristics. Table S6. Primary validation of positive association of ICP expression with OS. Table S7. Secondary validation of positive association of ICP expression with OS. Table S8. ICP RNA expression in normal vs. cancer tissues. Table S9. Validation of increased positive association with OS by ICP-TIL combination. Table S10. Validation of effect of IIC expression on OS. Table S11. Chromosomal locations of profiled ICP. Table S12. Association of TMA ICP combinations from MP-IF panels with OS. Table S13. Figure 5a correlogram common ICP groupings. Table S14. Figure S7 PC1 and PC2 groups positively associated with OS. Table S15. ICP- interactors having effects on K-M and modulated in their expression. Table S16. ICP-ICP interactors from IID. Table S17. Positive T cell functions of selected NSCLC patient stratifying ICPs. (ZIP 10706 kb)